| Aug 7 |
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
|
| Aug 7 |
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
|
| Aug 6 |
Guardant Health Q2 2024 Earnings Preview
|
| Aug 6 |
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
|
| Aug 1 |
Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat
|
| Aug 1 |
Guardant launches Shield colorectal cancer test in U.S.
|
| Aug 1 |
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
|
| Aug 1 |
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
|
| Jul 31 |
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|
| Jul 31 |
Is It Too Late To Consider Buying Guardant Health, Inc. (NASDAQ:GH)?
|
